Hongjiang Wu
Papers
1
Total Citations
350
H-Index
1
About
Hongjiang Wu is a leading figure in nucleic acid therapeutics, whose work has fundamentally shaped our understanding of how antisense drugs function at the molecular level. His research centers on the mechanistic biology of RNA degradation pathways, with a particular focus on the role of human RNase H enzymes in drug pharmacology. Wu’s landmark 2004 study, which has garnered over 350 citations, provided definitive evidence that human RNase H1 is the primary enzyme responsible for the target RNA cleavage induced by DNA-like antisense oligonucleotides. By systematically demonstrating that antisense activity is abolished in cells lacking RNase H1, he resolved a long-standing ambiguity in the field and established a critical mechanistic foundation for the rational design of therapeutic oligonucleotides. This seminal contribution has had a profound impact on the development of FDA-approved antisense drugs, guiding researchers in optimizing drug chemistry to engage RNase H1 effectively. Wu’s work remains essential reading for anyone seeking to understand the molecular pharmacology of nucleic acid-based medicines.
Research Focus
Key Achievements
Top Papers
- 1